Factors Affecting the Success of Step-up Therapy in Patients With Moderate-Severe Asthma: A Real-Life Study.


Journal

Journal of investigational allergology & clinical immunology
ISSN: 1018-9068
Titre abrégé: J Investig Allergol Clin Immunol
Pays: Spain
ID NLM: 9107858

Informations de publication

Date de publication:
20 Apr 2021
Historique:
pubmed: 14 12 2019
medline: 30 11 2021
entrez: 14 12 2019
Statut: ppublish

Résumé

Introduction: Clinical practice guidelines recommend regular adjustment of treatment to achieve control of asthma. A step-up approach based on the degree of disease control should be followed. Objective: To perform a real-life analysis of the factors that affect the success or failure of this therapeutic strategy and of the criteria applied by clinicians when applying a step-up approach in a representative sample of patients diagnosed with moderate-severe asthma. We performed a multicenter retrospective cohort study involving 226 Spanish specialist physicians (98 allergologists, 127 pulmonologists, and 1 family physician). We included 1254 patients (787 women) diagnosed with moderate-severe asthma who underwent step-up therapy during 2016. Step-up was successful in 44% of cases. The factors associated with success were presence of <2 comorbid conditions, lower grade of severity and therapy step before modification, absence of exacerbations during the previous year, fewer daytime/nighttime symptoms, and limitation in activities, as well as type of inhaled corticosteroid/ long-acting β₂-agonist combination after modification, lower body mass index, and higher fractional exhaled nitric oxide. An early increase in the maintenance dose once a lack of control was detected (≤3 months, >3 to ≤6 months, >6 to ≤12 months) was more likely to be successful. The factors that determine whether or not this therapeutic strategy manages to control asthma are time since onset of clinical impairment, previous grade of severity, number of comorbid conditions, previous exacerbations, and frequency of symptoms.

Identifiants

pubmed: 31833478
doi: 10.18176/jiaci.0470
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Adrenergic beta-2 Receptor Agonists 0
Drug Combinations 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

145-150

Auteurs

J Delgado (J)

Allergology Clinical Management Unit, Hospital Virgen Macarena, Sevilla, Spain.

E Martinez-Moragón (E)

Respiratory Medicine Department, Hospital Universitario Dr. Peset, Valencia, Spain.

T Fernández-Sánchez (T)

Medical Department, Mundipharma Pharmaceuticals, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH